TrialBridge

NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting · Phase 1, Phase 2 · MediLink Therapeutics (Suzhou) Co., Ltd. · registry updated 2026-06-18

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Inclusion

  • Age ≥ 18 years old.
  • Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.
  • ECOG PS score is 0 or 1.
  • Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.

Exclusion

  • Suitable for local curative treatment.
  • Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).
  • Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.
  • Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) \[anti-PD-(L)1\] or other immune checkpoint inhibitors.
  • History of bleeding tendency or coagulation disorders and/or clinically significant bleeding symptoms or risks within 4 weeks before randomization.
  • Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels.

Open NCT07208773 on ClinicalTrials.govAll conditions